EA034950B1 - Производные майтанзиноида, их конъюгаты и способы использования - Google Patents
Производные майтанзиноида, их конъюгаты и способы использования Download PDFInfo
- Publication number
- EA034950B1 EA034950B1 EA201700464A EA201700464A EA034950B1 EA 034950 B1 EA034950 B1 EA 034950B1 EA 201700464 A EA201700464 A EA 201700464A EA 201700464 A EA201700464 A EA 201700464A EA 034950 B1 EA034950 B1 EA 034950B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compound
- antibody
- implementations
- formula
- integer
- Prior art date
Links
- 0 CCC(C)(*)C(CCCCC(N[C@@](C(C)C)C(NC1(C(CCNC(N)=O)C1)C(Nc1cc(O)ccc1C(N(C[C@@]1(C[C@](C[C@]([C@@](C=CC=C(C)Cc(cc2OC)cc(N(C)C(C3)=O)c2Cl)OC)(N2)O)OC2=O)O[C@@]1(C)[C@]3O1)[C@@](C)C1=O)=O)=O)=O)=O)=O Chemical compound CCC(C)(*)C(CCCCC(N[C@@](C(C)C)C(NC1(C(CCNC(N)=O)C1)C(Nc1cc(O)ccc1C(N(C[C@@]1(C[C@](C[C@]([C@@](C=CC=C(C)Cc(cc2OC)cc(N(C)C(C3)=O)c2Cl)OC)(N2)O)OC2=O)O[C@@]1(C)[C@]3O1)[C@@](C)C1=O)=O)=O)=O)=O)=O 0.000 description 3
- BYRGDWLRLNGTCP-HWQNMXLQSA-N CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(Nc(ccc(C(N(C)[C@@H](C)C(O[C@@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]([C@@](C1)(N2)O)OC)cc3OC)c3Cl)=O)[C@]3(C)O[C@H]3C[C@H]1OC2=O)=O)=O)c1)c1N1CCOCC1)=O)=O)NC(NCCCCN(C(C=C1)=O)C1=O)=S Chemical compound CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(Nc(ccc(C(N(C)[C@@H](C)C(O[C@@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]([C@@](C1)(N2)O)OC)cc3OC)c3Cl)=O)[C@]3(C)O[C@H]3C[C@H]1OC2=O)=O)=O)c1)c1N1CCOCC1)=O)=O)NC(NCCCCN(C(C=C1)=O)C1=O)=S BYRGDWLRLNGTCP-HWQNMXLQSA-N 0.000 description 1
- PTMNMZKKROUAPP-HHGNYWQVSA-N CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(Nc1ccccc1C(N(C)[C@@H](C)C(O[C@@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]([C@@](C1)(N2)O)OC)cc3OC)c3Cl)=O)[C@]3(C)O[C@H]3C[C@H]1OC2=O)=O)=O)=O)=O)NC(NCCOCCOCCC(ON(C(CC1)=O)C1=O)=O)=S Chemical compound CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(Nc1ccccc1C(N(C)[C@@H](C)C(O[C@@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]([C@@](C1)(N2)O)OC)cc3OC)c3Cl)=O)[C@]3(C)O[C@H]3C[C@H]1OC2=O)=O)=O)=O)=O)NC(NCCOCCOCCC(ON(C(CC1)=O)C1=O)=O)=S PTMNMZKKROUAPP-HHGNYWQVSA-N 0.000 description 1
- ORAIJESRWGDJHB-XLDUQJBBSA-N CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(Nc1ccccc1C(N(C)[C@@H](C)C(O[C@@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]([C@@](C[C@H](C)C1)(NC(O)=O)O)OC)cc2OC)c2Cl)=O)[C@@H](C)[C@H]1O)=O)=O)=O)=O)NC(NCCCCN(C(C=C1)=O)C1=O)=S Chemical compound CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(Nc1ccccc1C(N(C)[C@@H](C)C(O[C@@H](CC(N(C)c(cc(C/C(/C)=C/C=C/[C@H]([C@@](C[C@H](C)C1)(NC(O)=O)O)OC)cc2OC)c2Cl)=O)[C@@H](C)[C@H]1O)=O)=O)=O)=O)NC(NCCCCN(C(C=C1)=O)C1=O)=S ORAIJESRWGDJHB-XLDUQJBBSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139044P | 2015-03-27 | 2015-03-27 | |
| US201562252239P | 2015-11-06 | 2015-11-06 | |
| PCT/US2016/024343 WO2016160615A1 (en) | 2015-03-27 | 2016-03-25 | Maytansinoid derivatives, conjugates thereof, and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201700464A1 EA201700464A1 (ru) | 2018-11-30 |
| EA034950B1 true EA034950B1 (ru) | 2020-04-09 |
Family
ID=55650789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201700464A EA034950B1 (ru) | 2015-03-27 | 2016-03-25 | Производные майтанзиноида, их конъюгаты и способы использования |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20160375147A1 (https=) |
| EP (1) | EP3273998B1 (https=) |
| JP (2) | JP6948950B2 (https=) |
| KR (2) | KR20240142591A (https=) |
| CN (2) | CN115645543A (https=) |
| AU (1) | AU2016243527B2 (https=) |
| BR (1) | BR112017020149A8 (https=) |
| CA (1) | CA2978340C (https=) |
| CL (1) | CL2017002422A1 (https=) |
| CO (1) | CO2017010890A2 (https=) |
| EA (1) | EA034950B1 (https=) |
| IL (1) | IL254267B (https=) |
| MX (2) | MX386328B (https=) |
| PH (1) | PH12017501780A1 (https=) |
| SG (1) | SG11201707148PA (https=) |
| WO (1) | WO2016160615A1 (https=) |
| ZA (1) | ZA201706040B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6847388B2 (ja) | 2013-03-15 | 2021-03-31 | レゲネロン ファーマシューティカルス，インコーポレーテッド | 生物活性分子、そのコンジュゲート、及び治療用途 |
| BR112016004023A2 (pt) | 2013-08-26 | 2022-11-16 | Regeneron Pharma | Composição, métodos para preparar uma composição e para tratar uma doença, e, composto |
| BR112017020149A8 (pt) * | 2015-03-27 | 2023-05-02 | Regeneron Pharma | Derivados de maitansinoide, conjugados dos mesmos e métodos de uso |
| JP6948708B2 (ja) | 2015-06-19 | 2021-10-13 | センチュリオン バイオファーマ コーポレイション | 薬物制御放出のための送達系 |
| IL296285A (en) | 2015-07-06 | 2022-11-01 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| BR112018014759B1 (pt) | 2016-01-25 | 2024-02-27 | Regeneron Pharmaceuticals, Inc | Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso |
| EP3448891A1 (en) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| JP7066690B2 (ja) | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| MY199468A (en) | 2016-09-23 | 2023-10-31 | Regeneron Pharma | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
| TWI782930B (zh) * | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| EP3548514A1 (en) | 2016-11-29 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Methods of treating prlr positive breast cancer |
| KR20200007905A (ko) | 2017-05-18 | 2020-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| DK3635009T3 (da) | 2017-06-07 | 2026-03-30 | Regeneron Pharma | Sammensætninger og fremgangsmåder til internalisering af enzymer |
| MX2020004691A (es) | 2017-11-07 | 2020-08-20 | Regeneron Pharma | Enlazadores hidrofilicos para conjugados anticuerpo-farmaco. |
| AU2018375788A1 (en) * | 2017-11-30 | 2020-07-09 | Ladrx Corporation | Maytansinoid-based drug delivery systems |
| KR102871690B1 (ko) | 2018-04-30 | 2025-10-16 | 리제너론 파마슈티칼스 인코포레이티드 | Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도 |
| BR112020023145A2 (pt) | 2018-05-17 | 2021-02-02 | Regeneron Pharmaceuticals, Inc. | anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto |
| CN112638426B (zh) * | 2018-09-21 | 2023-06-16 | 中国人民解放军军事科学院军事医学研究院 | 基于芳硝基的连接子、含连接子的抗体偶联药物及连接子的用途 |
| CA3128519A1 (en) | 2019-02-21 | 2020-08-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met |
| AU2020349462A1 (en) | 2019-09-16 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging |
| US11814428B2 (en) * | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
| EP4058024A1 (en) | 2019-11-15 | 2022-09-21 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate |
| CN113292574B (zh) * | 2020-02-21 | 2022-05-03 | 四川大学 | 一类手性多环的托品烷化合物及其制备方法和用途 |
| KR20220148200A (ko) | 2020-02-28 | 2022-11-04 | 리제너론 파마슈티칼스 인코포레이티드 | Her2에 결합하는 이중특이적 항원 결합 분자 및 이의 사용 방법 |
| CN115968304A (zh) | 2020-04-16 | 2023-04-14 | 瑞泽恩制药公司 | 狄尔斯-阿尔德缀合方法 |
| CA3190569A1 (en) | 2020-10-22 | 2022-04-28 | Christopher Daly | Anti-fgfr2 antibodies and methods of use thereof |
| US20220143194A1 (en) | 2020-11-10 | 2022-05-12 | Regeneron Pharmaceuticals, Inc. | Selenium antibody conjugates |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014080251A1 (en) * | 2012-11-24 | 2014-05-30 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| WO2014145090A1 (en) * | 2013-03-15 | 2014-09-18 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| JPS5566585A (en) * | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| EP1258255A1 (en) | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
| US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| US20110250133A1 (en) | 2003-01-13 | 2011-10-13 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| KR20130065723A (ko) | 2003-06-27 | 2013-06-19 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도 |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| NZ579482A (en) | 2004-06-01 | 2011-02-25 | Genentech Inc | Antibody drug conjugates and methods |
| JP2008521828A (ja) | 2004-11-29 | 2008-06-26 | シアトル ジェネティックス， インコーポレイテッド | 操作された抗体およびイムノコンジュゲート |
| US8603483B2 (en) | 2004-12-09 | 2013-12-10 | Janssen Biotech, Inc. | Anti-integrin immunoconjugates, methods and uses |
| DK1912677T3 (da) | 2005-06-20 | 2014-01-13 | Psma Dev Company L L C | PSMA-antistof-lægemiddel-konjugater |
| PL2135881T3 (pl) | 2005-06-20 | 2012-02-29 | Genentech Inc | Przeciwciała wiążące się z antygenem TAT10772 związanym z nowotworem, do diagnozowania i leczenia nowotworu |
| ATE535529T1 (de) | 2005-08-09 | 2011-12-15 | Millennium Pharm Inc | Verfahren zur acylierung von maytansinol mit chiralen aminosäuren |
| KR101352222B1 (ko) | 2005-12-22 | 2014-02-04 | 백스터 인터내셔널 인코포레이티드 | 의료용 제품에서 비-내독소 발열성 오염물을 보다 잘검출할 수 있는 개선된 단핵구 활성화 시험 |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| BRPI0717638A2 (pt) | 2006-10-27 | 2013-11-12 | Genentech Inc | Anticorpors e imunoconjugados e usos para os mesmos |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| CL2008001334A1 (es) | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| EP2167963B1 (en) | 2007-05-23 | 2019-04-17 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| DK2644194T3 (en) | 2008-03-18 | 2017-07-03 | Genentech Inc | Combinations of an anti-HER2 antibody-drug conjugate and docetaxel |
| SG189817A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
| AU2009275358C1 (en) | 2008-07-21 | 2015-09-24 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| EP2403538B1 (en) | 2009-03-04 | 2017-10-04 | Polytherics Limited | Conjugated proteins and peptides |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| AU2010283632B2 (en) | 2009-08-10 | 2016-08-25 | Ucl Business Plc | Reversible covalent linkage of functional molecules |
| TW201117814A (en) | 2009-10-02 | 2011-06-01 | Sanofi Aventis | New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody |
| UY32914A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Anticuerpos que se usan específicamente al receptor epha2 |
| CN102596922A (zh) | 2009-10-06 | 2012-07-18 | 免疫基因公司 | 有效的缀合物和亲水性连接体 |
| US8501692B2 (en) | 2009-12-14 | 2013-08-06 | The Regents Of The University Of Michigan | Compositions and methods for altering cocaine esterase activity |
| SI2528625T1 (sl) | 2010-04-15 | 2013-11-29 | Spirogen Sarl | Pirolobenzodiazepini in njihovi konjugati |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| SMT201700023T1 (it) | 2010-08-02 | 2017-03-08 | Regeneron Pharma | Topi che producono proteine leganti vl |
| RS53519B1 (sr) | 2010-09-01 | 2015-02-27 | Bayer Intellectual Property Gmbh | N-(tetrazol-5-il)- i n-(triazol-5-il)aril amidi karboksilne kiseline i njihova upotreba kao herbicida |
| EA201390575A1 (ru) | 2010-10-29 | 2014-01-30 | Иммьюноджен, Инк. | Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты |
| AU2011323316B2 (en) | 2010-11-03 | 2016-02-25 | Immunogen, Inc. | Cytotoxic agents comprising new ansamitocin derivatives |
| CA2836338C (en) | 2011-05-16 | 2022-05-03 | Koninklijke Philips N.V. | Tetrazine derivatives used in bio-orthogonal drug activation |
| CN110078789A (zh) | 2011-05-27 | 2019-08-02 | Ambrx 公司 | 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| JP6209159B2 (ja) | 2011-06-21 | 2017-10-04 | イミュノジェン・インコーポレーテッド | ペプチドリンカーを有する新規メイタンシノイド誘導体およびその結合体 |
| BR112014009070B1 (pt) | 2011-10-14 | 2021-11-23 | Medimmune Limited | Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas |
| EP2751111B1 (en) | 2011-10-14 | 2017-04-26 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases |
| CN103997893B (zh) | 2011-10-14 | 2019-04-12 | 西雅图基因公司 | 吡咯并苯并二氮杂卓和靶向结合物 |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| RU2014124984A (ru) | 2011-12-05 | 2016-01-27 | Идженика Биотерапьютикс, Инк. | Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы |
| GB201210770D0 (en) | 2012-06-18 | 2012-08-01 | Polytherics Ltd | Novel conjugation reagents |
| EP2861261A2 (en) | 2012-06-19 | 2015-04-22 | Polytherics Limited | Process for preparation of antibody conjugates and antibody conjugates |
| CN105142672B (zh) | 2012-10-23 | 2019-04-05 | 西纳福克斯股份有限公司 | 经修饰的抗体、抗体-缀合物及其制备方法 |
| NO2789793T3 (https=) | 2012-10-24 | 2018-01-27 | ||
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| CN104688740A (zh) | 2012-12-21 | 2015-06-10 | 百奥泰生物科技(广州)有限公司 | 类美登素衍生物及其制备方法和用途 |
| CN103254213B (zh) | 2012-12-21 | 2015-02-25 | 百奥泰生物科技(广州)有限公司 | 类美登素酯的制备方法及用于所述方法的组合物 |
| CN103254311B (zh) | 2013-05-09 | 2015-05-13 | 齐鲁制药有限公司 | 一种制备抗体-美登素类生物碱药物偶联物的方法 |
| WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| US20140363454A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-Drug Conjugates, Compositions and Methods of Use |
| US10781259B2 (en) | 2013-06-06 | 2020-09-22 | Magenta Therapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
| SG11201509982UA (https=) | 2013-06-06 | 2016-04-28 | Igenica Biotherapeutics Inc | |
| WO2014197854A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| BR112016004023A2 (pt) * | 2013-08-26 | 2022-11-16 | Regeneron Pharma | Composição, métodos para preparar uma composição e para tratar uma doença, e, composto |
| US20160354105A1 (en) | 2013-11-26 | 2016-12-08 | Segway Orthopaedics, Inc. | Surgical Blade with Viewing Aperture |
| CN115504924A (zh) | 2013-11-27 | 2022-12-23 | 雷德伍德生物科技股份有限公司 | 肼基-吡咯并化合物及用于生成缀合物的方法 |
| US9562059B2 (en) | 2013-12-02 | 2017-02-07 | Hong Kong Baptist University | Anticancer maytansinoids with two fused macrocyclic rings |
| US9951141B2 (en) | 2014-06-02 | 2018-04-24 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates, their preparation and their therapeutic use |
| BR112017020149A8 (pt) | 2015-03-27 | 2023-05-02 | Regeneron Pharma | Derivados de maitansinoide, conjugados dos mesmos e métodos de uso |
| BR112018014759B1 (pt) | 2016-01-25 | 2024-02-27 | Regeneron Pharmaceuticals, Inc | Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso |
| MY199468A (en) | 2016-09-23 | 2023-10-31 | Regeneron Pharma | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
| US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
-
2016
- 2016-03-25 BR BR112017020149A patent/BR112017020149A8/pt not_active Application Discontinuation
- 2016-03-25 KR KR1020247030839A patent/KR20240142591A/ko active Pending
- 2016-03-25 US US15/081,759 patent/US20160375147A1/en not_active Abandoned
- 2016-03-25 WO PCT/US2016/024343 patent/WO2016160615A1/en not_active Ceased
- 2016-03-25 CA CA2978340A patent/CA2978340C/en active Active
- 2016-03-25 MX MX2017012380A patent/MX386328B/es unknown
- 2016-03-25 KR KR1020177030678A patent/KR102708103B1/ko active Active
- 2016-03-25 CN CN202210829028.0A patent/CN115645543A/zh active Pending
- 2016-03-25 EA EA201700464A patent/EA034950B1/ru unknown
- 2016-03-25 AU AU2016243527A patent/AU2016243527B2/en active Active
- 2016-03-25 JP JP2017550548A patent/JP6948950B2/ja active Active
- 2016-03-25 CN CN201680030443.2A patent/CN107995912A/zh active Pending
- 2016-03-25 EP EP16714199.3A patent/EP3273998B1/en active Active
- 2016-03-25 SG SG11201707148PA patent/SG11201707148PA/en unknown
-
2017
- 2017-09-01 IL IL254267A patent/IL254267B/en active IP Right Grant
- 2017-09-05 ZA ZA2017/06040A patent/ZA201706040B/en unknown
- 2017-09-26 CL CL2017002422A patent/CL2017002422A1/es unknown
- 2017-09-27 PH PH12017501780A patent/PH12017501780A1/en unknown
- 2017-09-27 MX MX2021008101A patent/MX2021008101A/es unknown
- 2017-10-26 CO CONC2017/0010890A patent/CO2017010890A2/es unknown
-
2019
- 2019-12-12 US US16/712,941 patent/US20200385402A1/en not_active Abandoned
-
2021
- 2021-03-17 JP JP2021044152A patent/JP2021113191A/ja not_active Withdrawn
- 2021-11-16 US US17/528,144 patent/US12297207B2/en active Active
-
2025
- 2025-03-28 US US19/093,440 patent/US20250223299A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014080251A1 (en) * | 2012-11-24 | 2014-05-30 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| WO2014145090A1 (en) * | 2013-03-15 | 2014-09-18 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
Non-Patent Citations (1)
| Title |
|---|
| KAWAI A; ET AL: "CHEMICAL MODIFICATION OF ANSAMITOCINS 3. SYNTHESIS AND BIOLOGICAL EFFECTS OF 3 ACYL ESTERS OF MAYTANSINOL", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 32, no. 9, 1 January 1984 (1984-01-01), JP, pages 3441 - 3451, XP008094318, ISSN: 0009-2363 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12297207B2 (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| US20230116771A1 (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| TWI772288B (zh) | 基於艾日布林之抗體-藥物結合物及使用方法 | |
| KR20220156533A (ko) | IL-7Rα 결합 화합물 | |
| CA3011440C (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| HK1242628A1 (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| HK1242628B (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| HK1257219B (en) | Maytansinoid derivatives, conjugates thereof, and methods of use |